Nemvaleukin Alfa Plus Pembrolizumab Demonstrates Promising Responses, Disease Control in Platinum-Resistant Ovarian Cancer
March 20, 2022 9:55 amby Hayley Virgil
Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.
Treatment with nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) yielded tumor responses